Vancouver, British Columbia, Canada, October 20, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that it has launched a DNA testing program as part of its Nara.Care AI platform for personalized wellness.

 

Working with a leading developer of DNA testing technologies, the Company will market its Agenta branded DNA testing kits to health-conscious consumers in Canada as part of an initial roll-out campaign. The Company plans to expand marketing into the United States in early 2026.

 

“We believe consumers are looking for better information about their unique health situation to help guide their personal wellness plans”, said Maryam Marissen, President & CEO of PanGenomic Health. “The foundation of our NaraCare.AI platform is personalization, and there is no better baseline for that foundation than incorporating the unique genetic makeup of each individual.”

 

The Agenta DNA tests will deliver significant data into the Nara.Care AI platform that uses leading AI models to provide actionable insights into diet, fitness, metabolism, brain function and overall health and wellness. Given the sensitivity of genomic data, the Company will implement appropriate safeguards to protect the privacy of all health data.

 

The Agenta DNA testing kits will be available for purchase this quarter on the Agenta Health eCommerce site, which can be accessed at www.agentahealth.store.

 

About PanGenomic Health

 

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote alternative health solutions tailored to the health profile of each individual. To learn more about PanGenomic Health’s products and services: www.pangenomic.com or email: info@pangenomic.com.

 

For more information, please contact:

 

Fairfax Partners Inc. Daniel Southan-Dwyer, President +1 604 305 5369 fair@fairfax.partners

 

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe”, “plans” and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health’s disclosure documents which can be found under PanGenomic Health’s profile on www.sedarplus.ca.  These risk factors include the possibility of delays in PanGenomic Health’s development or product launch efforts, PanGenomic Health not having sufficient financial resources to complete its development or product launch efforts in a timely manner and other risks, including those that may be outside of the control of PanGenomic Health.  Except as required under applicable securities legislation, PanGenomic Health undertakes no obligation to publicly update or revise forward-looking statements.

 

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.